The Herschel Reference Survey Boselli, A.; Eales, S.; Cortese, L. ...
Publications of the Astronomical Society of the Pacific,
03/2010, Letnik:
122, Številka:
889
Journal Article
Recenzirano
Odprti dostop
The Herschel Reference Survey is a Herschel guaranteed time key project and will be a benchmark study of dust in the nearby universe. The survey will complement a number of other Herschel key ...projects including large cosmological surveys that trace dust in the distant universe. We will use Herschel to produce images of a statistically-complete sample of 323 galaxies at 250, 350, and 500 μm. The sample is volume-limited, containing sources with distances between 15 and 25 Mpc and flux limits in the
K
K
band to minimize the selection effects associated with dust and with young high-mass stars and to introduce a selection in stellar mass. The sample spans the whole range of morphological types (ellipticals to late-type spirals) and environments (from the field to the center of the Virgo Cluster) and as such will be useful for other purposes than our own. We plan to use the survey to investigate (i) the dust content of galaxies as a function of Hubble type, stellar mass, and environment; (ii) the connection between the dust content and composition and the other phases of the interstellar medium; and (iii) the origin and evolution of dust in galaxies. In this article, we describe the goals of the survey, the details of the sample and some of the auxiliary observing programs that we have started to collect complementary data. We also use the available multifrequency data to carry out an analysis of the statistical properties of the sample.
We have determined the cosmological evolution of the density of active galactic nuclei (AGNs) and of their N sub(H) distribution as a function of the unabsorbed 2-10 keV luminosity up to redshift 4. ...We used the HELLAS2XMM sample combined with other published catalogs, yielding a total of 508 AGNs. Our best fit is obtained with a luminosity-dependent density evolution (LDDE) model where low-luminosity (L sub(X) 6 10 super(43) ergs s super(-1)) AGNs peak at z 6 0.7, while high-luminosity AGNs (L sub(X) > 10 super(45) ergs s super(-1)) peak at z 6 2.0. A pure luminosity evolution model (PLE) can instead be rejected. There is evidence that the fraction of absorbed (N sub(H) > 10 super(22) cm super(-2)) AGNs decreases with the intrinsic X-ray luminosity and increases with the redshift. Our best-fit solution provides a good fit to the observed counts, the cosmic X-ray background, and to the observed fraction of absorbed AGNs as a function of the flux in the 10 super(-15) ergs cm super(-2) s super(-1) < S sub(2)-10 < 10 super(-10) ergs cm super(-2) s super(-1) range. We find that the absorbed, high-luminosity (L sub(X) > 10 super(44) ergs s super(-1)) AGNs have a density of 267 deg super(-2) at fluxes S sub(2-10) > 10 super(-15) ergs cm super(-2) s super(-1). Using these results, we estimate a density of supermassive black holes in the local universe of r sub(BH) = 3.2 h sub(70) super(2) x 10 super(5) M sub(z) Mpc super(-3), which is consistent with the recent measurements of the black hole mass function in the local galaxies.
In Italy, an HLA-matched unrelated donor is currently the primary donor when a HLA matched sibling is not found for allogeneic haematopoietic stem cell transplantation (HSCT). Better outcomes for ...transplantation require optimal matching between donor and recipient at least at the HLA-A, -B, -C, and -DRB1 loci; therefore, the availability of HLA-matched unrelated donors is important. The enormous HLA polymorphism has always necessitated registries with a large number of individuals in order to be able to provide well-matched donors to a substantial percentage of patients. In order to increase the efficiency of the Italian Bone Marrow Donor Registry (IBMDR) in providing Italian patients with a suitable donor, the probability of finding an HLA-A, -B, -C, and -DRB1 allele-matched (8/8) or a single mismatch unrelated donor (7/8) was estimated in this study according to IBMDR size. Using a biostatistical approach based on HLA haplotype frequencies of more than 100,000 Italian donors enrolled in the IBMDR and HLA-typed at high-resolution level, the probability of finding an 8/8 HLA-matched donor was 23.8%; 33.4%; and 41.4% in simulated registry sizes of 200,000; 500,000; and 1,000,000 donors; respectively. More than 2 million recruited donors are needed to increase the likelihood of identifying an HLA 8/8 matched donor for 50% of Italian patients.
If one single mismatch at HLA I class loci was accepted, the probability of finding a 7/8 HLA-matched donor was 62.8%; 73.7%; and 80.3% in 200,000 donors; 500,000; and 1,000,000 donors; respectively.
Using the regional haplotype frequencies of IBMDR donors, the probability of recruiting a donor with a new HLA phenotype, in the different Italian regions, was also calculated. Our findings are highly relevant in estimating the optimal size of the national registry, in planning a cost-effective strategy for donor recruitment in Italy, and determining the regional priority setting of recruitment activity in order to increase the phenotypic variability of IBMDR as well as its efficiency.
We use Herschel Space Observatory data to place observational constraints on the peak and Rayleigh-Jeans slope of dust emission observed at 70–500 μm in the nearby spiral galaxy M81. We find that the ...ratios of wave bands between 160 and 500 μm are primarily dependent on radius but that the ratio of 70 to 160 μm emission shows no clear dependence on surface brightness or radius. These results along with analyses of the spectral energy distributions imply that the 160–500 μm emission traces 15–30 K dust heated by evolved stars in the bulge and disc whereas the 70 μm emission includes dust heated by the active galactic nucleus and young stars in star forming regions.
We present the observations of the starburst galaxy M82 taken with the Herschel SPIRE Fourier-transform spectrometer. The spectrum (194–671 μm) shows a prominent CO rotational ladder from J = 4–3 to ...13–12 emitted by the central region of M82. The fundamental properties of the gas are well constrained by the high J lines observed for the first time. Radiative transfer modeling of these high-S/N 12CO and 13CO lines strongly indicates a very warm molecular gas component at ~500 K and pressure of ~3×106 K cm-3, in good agreement with the H2 rotational lines measurements from Spitzer and ISO. We suggest that this warm gas is heated by dissipation of turbulence in the interstellar medium (ISM) rather than X-rays or UV flux from the straburst. This paper illustrates the promise of the SPIRE FTS for the study of the ISM of nearby galaxies.
We have previously shown that hemopoietic stem cell transplant (HSCT) recipients can be stratified on day+7 as having low, intermediate or a high risk of transplant-related mortality (TRM). With the ...aim of reducing TRM and GVHD, intermediate and high-risk patients (n=170) were randomized to receive anti-thymocyte globulin (ATG, thymoglobuline) on day+7 (n=84) or no treatment (n=86) (controls). There was a reduction of TRM from 35% in controls to 29% in ATG patients (P=0.3), of acute GVHD III-IV from 15 to 5% (P=0.02) and of chronic GVHD from 26 to 11% (P=0.03); survival was comparable. The predictive value of the day+7 score on TRM was confirmed for controls (19 vs 42% for intermediate vs high risk, respectively, P=0.03), whereas ATG abrogated this predictive effect (29 vs 29%). ATG reduced GVHD (P=0.006) in high-risk patients, but not in patients with an intermediate risk. In conclusion, we confirm that TRM can be predicted on the basis of day+7 laboratory values, after alternative donor HSCT; in high-, but not intermediate-risk patients, the administration of ATG on day+7 reduces GVHD. These results may represent a platform for risk-adapted post transplant immune modulation.
Chronic GVHD (cGVHD) has been associated with reduced risk of relapse after allo-SCT for onco-hematological disease due to a graft-vs-malignancy effect. Here we retrospectively analyzed a series of ...802 adult patients transplanted from unrelated donors and found that cGVHD was associated with significantly lower relapse and that the limited form was associated with a survival advantage: hazard ratio for OS=0.63 (0.46-0.87); P=0.004; this was due to combination of relapse reduction and similar non-relapse mortality with respect to patients without cGVHD. Importantly, the graft-vs-malignancy effect observed here did not differ when PBSC or BM were used as stem cell source, thus suggesting that the protective effect of limited cGVHD is similar after PBSC- or BM-based transplantation. These findings could have practical implications and suggest no qualitative difference between cGVHD occurring after transplantation performed with different stem cell sources.
Uncertainty still exists on the role of polymorphisms outside the HLA-DRB1 binding site or inside the HLA-DRB3 binding groove in unrelated hematopoietic SCT (HSCT). The ideal model to solve the ...conundrum consists of the transplants mismatched for HLA-DRB1*14:01/*14:54 and/or for HLA-DRB3*02:01/*02:02. A task force was set up in Italy to recruit transplanted pairs defined as HLA-DRB1*14:01 before 2006, the year crucial for the proper definition of the HLA-DRB1*14:54 allele in molecular biology. Out of 2723 unrelated pairs, 189 transplanted in Italy from 1995 to 2006 were HLA-DRB1*14:01 positive; 103/189 pairs with good historical DNA were retyped for HLA-DRB1*14 and HLA-DRB3 at-high resolution level; 31/103 pairs had HLA-DRB1*14 and/or HLA-DRB3 mismatched; 99/103, having complete clinical data, underwent statistical analysis for OS, TRM, disease-free survival and acute and chronic GvHD. No significant involvement of HLA-DRB1*14:01/*14:54 or HLA-DRB3*02:01/*02:02 mismatches was found, either alone or combined. Our findings suggest that disparities at exon 3 of the HLA-DRB1 gene seem unlikely to influence the outcome after HSCT. The same may be envisaged for HLA-DRB3(*)02:01 and (*)02:02 alleles which, although differing in the Ag binding site, seem unable to modulate an appreciable immune response in an HSCT setting.
PDF
